Patient Involvement in HTA

Die Themen

- Evolving Role of Patient Advocates in EU HTA - Patient Engagement with NICE: Lessons from the UK - The Role of Patients in Germany's AMNOG Process - Patient Involvement in Clinical Trial Designs and Decision Making - Patient-Reported Outcomes - Collaboration with Patient Organisations

Ziele

This course offers comprehensive insights into the evolving role of patients and patient advocates in HTA processes across Europe. You will explore how and when patients are involved, drawing on both national experiences and European regulatory frameworks.

- The agenda includes perspectives on NICE, the AMNOG process, the new EU HTA regulation, and methodological aspects such as patient-reported outcomes and further outcome measures. You will gain a deep understanding of the value and impact of patient contributions to HTA, supported by real-world examples and best practices.

Wer sollte teilnehmen?

This course is intended for professionals in the pharmaceutical industry involved in outcomes research, health technology assessment (HTA), and market access who wish to foster patient involvement. A sound understanding of HTA principles is required.